The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro

Medical Oncology

Volumn 30, Issue 3, 2013, Pages

  Yavasoglu, Irfan ^a   Sargin, Gokhan ^a   Kadikoylu, Gurhan ^a   Karul, Aslihan ^a   Bolaman, Zahit ^a  

^a ADNAN MENDERES UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Chronic lymphocytic leukemia; In vitro

Indexed keywords

ATORVASTATIN; CD38 ANTIGEN; CD5 ANTIGEN; HEMOGLOBIN; LIPOCORTIN 5; PROTEIN BCL 2; PROTEIN KINASE ZAP 70; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CALCIUM; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; ZAP70 PROTEIN, HUMAN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HEMATOCRIT; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE COUNT; LYMPHOCYTE; LYMPHOCYTE COUNT; MONONUCLEAR CELL; PRIORITY JOURNAL; THROMBOCYTE COUNT; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; DRUG EFFECTS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANNEXIN A5; ANTIGENS, CD38; ANTIGENS, CD5; APOPTOSIS; CALCIUM; FEMALE; HEPTANOIC ACIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; THIAZOLIDINEDIONES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84877725400     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0603-y     Document Type: Article

References (48)

1. Johston JB, Seftel M, Gibson SB. Chronic lymphocytic leukemia. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT, editors. Wintrobe's clinical hematology. 12th ed. Philadolphia: Lippincott Williams and Wilkins; 2009. p. 2214-55.
2. Chapman-Shimshoni D, Yuklea M, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol. 2003;31:779-83.
3. Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogeninduced proliferation of malignant B-lymphocytes from humansin vitro and in vivo studies. Lipids. 1997;32:255-62.
4. Padilla J, Kaur K, Cao HJ, Smith TJ, Phipps RP. Peroxisomeproliferator activator receptor-c agonists and 15-deoxy-D12,14- PGJ2 induce apoptosis in normal and malignant B-lineage cells. J Immunol. 2000;165:6941-8.
5. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-γ and are killed by PPAR-γ agonists. Clin Immunol. 2002;103:22-33.
6. Jo SH, Yang C, Miao Q, Marzec M, Wasik MA, Lu P, et al. Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities. J Immunol. 2006;177:3737-45.
7. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16: 508-19.
8. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-7.
9. Panayiotidis P, Ganeshguru K, Jabbar SAB, Hoffbrand AV. Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukemia cells in vitro. Br J Heamatol. 1993;85:439.
10. Mainou-Fowler T, Craig VA, Copplestone AJ, Hamon MD, Prentice AG. Effect of anti-APO1 on spontaneous apoptosis of B cells in chronic lymphocytic leukaemia: the role of bcl-2 and interleukin-4. Leuk Lymphoma. 1995;19:301-8.
11. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.
12. Ertault-Daneshpouy M, Noguera ME, Gisselbrecht C, Haddad A, Brice P, Marolleau JP, et al. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2008;6:55-63.
13. Lawen A. Apoptosis-an introduction. BioEssays. 2003;25:888-96.
14. Sanz L, Garcia-Marco JA, Casanova B, de La Fuente MT, Garcia-Gila M, Garcia-Pardo A, et al. Bcl-2 family gene modulation during spontaneous apoptosis of B-chronic lymphocytic leukemia cells. Biochem Biophys Res Commun. 2004;315:562-7.
15. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-89.
16. Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol. 2004;75:22-33.
17. Konopleva M, Elstner E, McQueen T, Tsao T, Sudarikov A, Hu W, et al. Peroxisome proliferator-activated receptor; and retinoid Xreceptor ligands are potent inducers of differentiation and apoptosis in leukemias. Mol Cancer Ther. 2004;3:1249-62.
18. Gardner OS, Shiau CW, Chen CS, Graves LM. Peroxisome proliferator- activated receptor gamma-independent activation of p38 MAPK by thiazolidinediones involves calcium/calmodulindependent protein kinase II and protein kinase R: correlation with endoplasmic reticulum stress. J Biol Chem. 2005;280:10109-18.
19. Eucker J, Bangeroth K, Zavrski I, Krebbel H, Zang C, Heider U, et al. Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma. Anticancer Drugs. 2004;15:955-60.
20. Groves MJ, Maccallum S, Boylan MT, Coates PJ, Tauro S. The annexin-V assay reflects susceptibility to in vitro membrane damage in chronic lymphocytic leukemia and may overestimate cell death. Am J Hematol. 2009;84:196-7.
21. Castejón R, Yebra M, Citores MJ, Villarreal M, García-Marco JA, Vargas JA. Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2009;50:593-603.
22. Spady DK, Dietschy JM. Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat. J Lipid Res. 1983;24:303-15.
23. Simons K, Ikonen E. Functional lipid rafts in cell membranes. Nature. 1997;387:569-72.
24. Robinson MJ, Cheng M, Khokhlatchev A, Ebert D, Ahn N, Guan KL, et al. Contributions of the mitogen-activated protein (MAP) kinase backbone and phosphorylation loop to MEK specificity. J Biol Chem. 1996;271:29734-9.
25. O'Donnell MP, Kasiske BL, Massy ZA, Guijarro C, Swan SK, Keane WF. Isoprenoids and Ras: potential role in chronic rejection. Kidney Int. 1995;52:29-33.
26. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as newly recognized type of immunomodulator. Nat Med. 2000;12:1399-402.
27. Brumeanu TD, Goldstein R, Casares S. Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin Immunol. 2006;119:1-12.
28. Hillyard DZ, Cameron AJ, McIntyre AH, Hadden MH, Marshall HE, Johnston N, et al. Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharmacol Physiol. 2002;8:673-8.
29. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, et al. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004;175:83-90.
30. Branco-Colio LM, Munoz-Garcia B, Martin-Ventura JL, Lorz C, Diaz C, Hernandez G, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes. Circulation. 2003;108:1506-13.
31. Lawman S, Mauri C, Jury EC, Cook HT, Ehrenstein MR. Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand Black/White F1 mice. J Immunol. 2004;173:7641-6.
32. Ajith TA, Soja M. A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens. Cell Biol Toxicol. 2006;22:269-74.
33. Ajith TA, Harikumar KB, Thasna H, Sabu MC, Babitha NV. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice. Clin Chim Acta. 2006;366:322-8.
34. Ajith TA, Anu V, Riji T. Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice. J Exp Ther Oncol. 2008;7:291-8.
35. Ajith TA, Riji T, Anu V. In vitro anti-oxidant and DNA protective effects of the novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin. Clin Exp Pharmacol Physiol. 2008;35:625-9.
36. Podhorecka M, Halicka D, Klimek P, Kowal M, Chocholska S, Dmoszynska A. Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells. Ann Hematol. 2010;89:1115-24.
37. Drake DR, Braciale TJ. Cutting edge: lipid rafts integrity affects the efficiency of MHC class I tetramer binding and cell surface TCR arrangement on CD8 + T cells. J Immunol. 2001;166: 7009-13.
38. Cheng PC, Dykstra ML, Michell RN, Pierce SK. A role of lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med. 1999;190:1549-60.
39. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity. 1998;8:723-32.
40. Sarrabayrouse G, Synaeve C, Leveque K, Favre G, Tilkin-Mariamé AF. Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia. 2007;9:1078-90.
41. Tomiyama N, Yasuda N, Iwano C, Matzno S, Matsuyama K. Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts. Clin Exp Pharmacol Physiol. 2007;34:876-80.
42. Gajski G, Garaj-Vrhovac V, Orescanin V. Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: standard and Fpg-modified comet assay. Toxicol Appl Pharmacol. 2008;231:85-93.
43. Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005;26:883-91.
44. Blank N, Schiller M, Krienke S, Busse F, Schätz B, Ho AD, et al. Atorvastatin inhibits T cell activation through 3-hydroxy-3- methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis. J Immunol. 2007;179:3613-21.
45. Ray DM, Akbiyik F, Phipps RP. The peroxisome proliferatoractivated receptor gamma (PPARgamma) ligands 15-deoxy-Delta12,14-prostaglandin J2 and ciglitazone induce human B lymphocyte and B cell lymphoma apoptosis by PPARgammaindependent mechanisms. J Immunol. 2006;177:5068-76.
46. Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD, et al. Down regulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol. 2007;86:173-83.
47. Bairey O, Vanichkin A, Shpilberg O. Arsenic-trioxide-induced apoptosis of chronic lymphocytic leukemia cells. Int J Lab Hematol. 2010;32:77-85.
48. Boelens J, Lust S, Van Bockstaele F, Van Gele M, Janssens A, Derycke L, et al. Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia. Leuk Res. 2009;33:1335-43.